Effector Therapeutics, INC
Market Movers (8-K)
OTC.Pink
eFFECTOR Therapeutics received a notice of default from Oxford Finance, triggering immediate repayment of all loan obligations.
Worse than expected
Capital raise
OTC.Pink
eFFECTOR Therapeutics received notice from Nasdaq that its stock will be delisted due to the company's plans to wind down operations and failure to meet listing requirements.
Worse than expected
OTC.Pink
8-K: eFFECTOR Therapeutics Announces Operational Wind-Down, Delisting from Nasdaq, and Leadership Change
eFFECTOR Therapeutics will terminate operations, seek strategic alternatives, delist from Nasdaq, and has appointed a new CEO to manage the wind-down process.
Worse than expected
OTC.Pink
eFFECTOR Therapeutics has increased its authorized common stock shares from 40 million to 80 million after a successful vote at its 2024 Annual Meeting of Stockholders.
Capital raise
OTC.Pink
eFFECTOR Therapeutics will collaborate with Dana-Farber Cancer Institute to conduct a Phase 2 trial evaluating zotatifin in combination with other drugs for certain cancers.
OTC.Pink
eFFECTOR Therapeutics has received a notice from Nasdaq for failing to meet the minimum market value requirement for continued listing, giving them until November 12, 2024, to regain compliance.
Worse than expected
Quarterly Earnings (10-Q)
OTC.Pink
10-Q: eFFECTOR Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
eFFECTOR Therapeutics reports its financial results for the first quarter of 2024, highlighting key financial metrics and providing updates on its clinical development programs.
Capital raise
Worse than expected
Annual Reports (10-K)
OTC.Pink
eFFECTOR Therapeutics' 10-K filing highlights ongoing clinical trials for its lead drug candidates and its financial position, including a need for additional capital.
Delay expected
Capital raise
Worse than expected